| Management of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization. | |
| | |
MedLine Citation:
|
PMID: 18533739 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The immediate goal of reperfusion in acute ST-elevation myocardial infarction (STEMI) is the prompt restoration of myocardial blood flow. Over the past 50 years, numerous advances have been made in achieving this goal by combining pharmacologic regimens with primary percutaneous coronary intervention (PCI) [i.e. pharmacoinvasive recanalizaton]. Fibrinolytics and glycoprotein (GP) IIb/IIIa inhibitors remain the most promising and widely used pharmacologic agents used to date. Early GP IIb/IIIa inhibition in patients undergoing PCI for STEMI results in early reperfusion and can result in improved clinical outcomes. Combination therapy with fibrinolytics and GP IIb/IIIa inhibitors is currently under investigation. The importance of time in the administration of these agents, especially in patients with expected delays to mechanical reperfusion, cannot be overemphasized. Benefits of revascularization are dependent on establishing reperfusion early enough to salvage the myocardium and preserve the left ventricular ejection fraction. As time passes, the effectiveness of treatments decline and patient outcomes are worse. This dependence upon time applies to both fibrinolytic therapy as well as primary PCI. In the current era, primary PCI is the preferred modality for treating patients with STEMI with a goal door-to-balloon time of <90 minutes. However, this modality is not available to all patients presenting with STEMI. Given the importance of time to reperfusion, a pharmacoinvasive approach may be ideal for this patient population. In this paper, we review the literature on pharmacoinvasive recanalization and discuss the optimal combination and timing of these agents. We have linked current American College of Cardiology/American Heart Association Clinical Practice Guidelines to clinical data available in the literature. |
| | |
Authors:
|
Amir Kashani; Robert P Giugliano |
Related Documents
:
|
23140789 - Stabilizing endothelium of donor hearts with fusogenic liposomes reduces myocardial inj... 16264199 - Release and elimination of soluble vasoactive factors during percutaneous coronary inte... 23729839 - Patient-specific models of cardiac biomechanics. 16700859 - A review of the management of patients after percutaneous coronary intervention. 23524949 - Isolation and kv channel recordings in murine atrial and ventricular cardiomyocytes. 19822979 - Partial vs full coverage for tandem lesions in culprit vessel during primary coronary i... 3181179 - Modification of a left-sided accessory atrioventricular pathway by radiofrequency curre... 15913489 - Is hypertension a prothrombotic state? 10607359 - Fetal discrimination of low-pitched musical notes. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of cardiovascular drugs : drugs, devices, and other interventions Volume: 8 ISSN: 1175-3277 ISO Abbreviation: Am J Cardiovasc Drugs Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-06-06 Completed Date: 2008-11-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100967755 Medline TA: Am J Cardiovasc Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 187-97 Citation Subset: IM |
Affiliation:
|
Section of Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary* Combined Modality Therapy Controlled Clinical Trials as Topic Dose-Response Relationship, Drug Drug Therapy, Combination Fibrinolytic Agents / administration & dosage, therapeutic use* Humans Myocardial Infarction / therapy* Platelet Aggregation Inhibitors / administration & dosage, therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Next Document: Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective stu...